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INTRODUCTION
Papillary thyroid carcinoma (PTC) is the most common
type of thyroid malignancy (1, 2) and several genes have been
implicated in the carcinogenesis of PTC, including TP53,
p21, met, trk and ras (3). Recently, however, the rearrange-
ment of RET proto-oncogene, which is normally expressed in
neural crest-derived tissues but not in thyroid follicular cells,
has been reported to be the most common genetic change in
the development of PTC (4). The RET proto-oncogene maps
to the long arm of chromosome 10 and encodes a cell mem-
brane-bound receptor tyrosine kinase (5). When the tyrosine
kinase encoding domain of the RET proto-oncogene under-
goes fusion with the 5 -terminal region of another gene that
is constitutively expressed, it results in activation of an onco-
gene designated RET/PTC. As a consequence, the products
of the chimeric RET/PTC oncogenes lead to the relocation
of the ret tyrosine kinase domain from the membrane to the
cytoplasm and display constitutive tyrosine-kinase activity
by autophosphorylation (6-8).
Such rearrangements of the RET proto-oncogene have only
been found in thyroid gland tumors of the papillary histo-
type. However, its prevalence has been reported variably in
different geographical regions (9-12), and its correlation with
clinical outcome has been controversial (2, 6, 13-15). 
The purpose of this current study is first to evaluate the
expression rate of Ret protein in a large series of classic PTCs
in a Korean population using immunohistochemistry in tis-
sue microarray and explore its possibility as a reliable prog-
nostic factor by analyzing its correlation with known prognos-
tic factors. Secondly, this study is intended to clarify a more
specific role of Ret antibody as an ancillary tool for diagnos-
ing PTC in conjunction with cytokeratin (CK) 19. 
Recent studies of CK19 expression in thyroid neoplasms
have demonstrated that various low and high molecular-weight
CKs in general are expressed differentially in PTCs (16, 17).
In particular, CK19 is reported to be limited to PTCs, thus
favoring the diagnosis of PTC in all its variant patterns (18).
Sahoo et al. has reported that immunoreactivity for CK19 is
not specific for PTC, although the extent and intensity of
staining are significantly greater in PTC than in follicular
adenoma (19). However, most of the previous studies have
proposed CK19 to be a useful immunohistochemical mark-
er to distinguish PTC from other benign and malignant fol-
licular lesions (17, 20, 21).
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RET/PTC and CK19 Expression in Papillary Thyroid Carcinoma and
Its Clinicopathologic Correlation
Recently, the rearrangement of RET proto-oncogene has been reported to be the
most common genetic change in papillary thyroid carcinoma (PTC). However, its
prevalence has been reported variably and its relation to clinical outcome has
been controversial. The characteristic nuclear features of PTC usually render the
diagnosis, but problem arises with equivocal cytologic features that are present
focally. Although there remains some controversy, CK19 has been reported to be
a useful ancillary tool for diagnosis of PTC. To evaluate the expression rate of
RET/PTC rearrangement and CK19 in PTCs in a Korean population, we studied
115 papillary thyroid carcinomas in 3 mm-core tissue microarray based immuno-
histochemical analysis. The prevalence of Ret protein expression was 62.6% and
the CK19 immunoreactivity was 80.9%. There was no statistically significant asso-
ciation between the Ret positivity and CK19 immunoreactivity, although the per-
cent agreement of the two was relatively high. The clinicopathological variables
did not correlate with the expression of Ret. In conclusion, the prevalence of Ret
protein expression and its clinicopathological implications in a Korean population
are not much different from those reported in previous studies. However, its detec-
tion via immunohistochemistry can be a useful diagnostic tool for diagnosing papil-
lary thyroid carcinoma in conjunction with CK19.
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MATERIALS AND METHODS
Patient selection
The surgical pathology files of Department of Pathology
in Yonsei University College of Medicine in Seoul, Korea, in
the year 2001 were searched for ‘papillary carcinoma’ in thy-
roid. After review of the search results, a consecutive series
of 115 classic PTCs were selected for the study. All variants
including follicular variant were excluded to maintain the
reproducibility and the representativeness of the results. Clin-
ical data were obtained from the medical records.
Histopathology, tissue microarray construction, and
immunohistochemistry
The slides of 115 cases were reviewed with special atten-
tion to the diagnostic nuclear features of PTC, i.e. nuclear
grooves, intranuclear inclusions and nuclear clearing (1), and
papillary structures to identify representative areas of the spec-
imen for tissue microarray. From these defined areas core biop-
sies were taken with a precision instrument. Tissue cores with
a diameter of 3 mm from each specimen were punched and
arrayed on a recipient paraffin block. 4- m sections of these
tissue array blocks were cut and used for immunohistochemi-
cal analysis (Fig. 1, 2). Normal thyroid tissue distant from the
i) tumor area, ii) adenomatous nodule, and iii) inflammatory
cell infiltrates were obtained from each specimen and arrayed.
These arrayed normal tissues served as baseline controls. 
Sections from tissue arrays were deparaffinized in xylene,
rehydrated in graded alcohols, and processed using the labeled
streptavidin-biotin-peroxidase method. Briefly, sections were
submitted to antigen retrieval for 15 min in 44% formic acid
for Ret and in 0.4% pepsin for CK19, both at room tem-
perature. Slides were subsequently incubated in 10% nor-
mal blocking serum for 30 min. They were then incubated
overnight at 4℃ in appropriately diluted primary antibody.
Rabbit polyclonal anti-Ret (1:200; Santa Cruz Biotechnolo-
gy, Santa Cruz, CA, U.S.A.) antibody and mouse monoclon-
al anti-CK19 (1:75; Biomeda, Hayward, CA, U.S.A.) anti-
body were used. After washing with Tris buffer, sections were
incubated with biotin-labelled secondary antibodies and then
with streptavidin-horseradish peroxidase using the DAKO
LSAB kit (DAKO, Carpinteria, CA, U.S.A.) at room tem-
perature for 30 min for each step. Nova red (Vector Labora-
tory, Burlingame, CA, U.S.A.) was used as the chromogen
and hematoxylin as the nuclear counterstain. This procedure
was performed for all antibodies under study. The sections
were also stained with antibodies to thyroglobulin (1:500,
DAKO, Glostrup, Denmark), thyroid transcription factor-1
(1:100, DAKO, Glostrup, Denmark), and calcitonin (1:200,
DAKO, Glostrup, Denmark) to validate the follicular cell
origin of each case. Cases with thyroglobulin and thyroid tran-
scription factor-1 positivity and calcitonin negativity were
selected only. 
Diffuse cytoplasmic staining of the tumor cells was defined
as positive immunoreactivity for Ret and CK19. Informations
on regional lymph node metastasis, perithyroidal extension
Fig. 1. (A) 4- m section of tissue microarray stained with H&E,
showing 3 mm cores of papillary thyroid carcinomas and matched
normal thyroid tissues. (B) Immunohistochemical stain for Ret anti-
body. (C) Immunohistochemical stain for CK19. 
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of the tumor, multiplicity at the time of diagnosis, and size of
the tumor were assessed from the surgical pathology reports.
Statistical analysis
Summary statistics were obtained using established meth-
ods. Associations between Ret immunoreactivity and each
variable, i.e. lymph node metastasis, perithyroidal extension
and multiplicity, were evaluated using the chi-square test.
Kappa statistics was performed for the evaluation of percent
agreement, the extent to which Ret immunoreactivity and
CK19 immunoreactivity concur. 
In all statistical analyses, a two-tailed p value ≤0.05 was
considered statistically significant. All analyses were performed
using SPSS for Windows statistical software (Version 10.0). 
RESULTS
Clinicopathological data
The male to female ratio of the patient group was 1:10.5,
which was similar in both Ret positive and negative groups.
The average age at surgery was 44.5 yr, with a range from 19-
76 yr (Table 1). Twenty-nine patients had multifocal disease,
and 84 patients had single tumors. Information on the mul-
tiplicity of the tumor at the time of the surgery was not avail-
able in two patients. The average tumor size was 1.8 cm with
a range from 0.5 cm to 6.0 cm. The size of the tumor was
not mentioned in the surgical pathology reports in 6 patients.
Of the remaining 109 tumors, 37 cases were less than 1 cm,
68 were in the range of 1-4 cm, and only 4 cases were more
than 4 cm (Table 2). Eighty-five patients underwent region-
al lymph node dissection, of which 63 had lymph node metas-
tasis. Perithyroidal extension was present in 84 cases and 29
cases had tumors confined to the thyroid parenchyma (Table
2). The presence of perithyroidal extension was not evaluable
Ret
p-value
Positive Negative
Age (yr) p=0.55
Mean 44.5±13.4 45.1±13.2 43.6±13.8
Range 19-76 20-68 19-76
≤40 43 24 (55.8%) 19 (16.5%)
>40 72 48 (66.7%) 24 (33.3%)
Sex p=1.00
Female 105 66 (62.9%) 39 (37.1%)
Male 10 6 (60.0%) 4 (40.0%)
Table 1. Clinical data and their correlation with Ret protein ex-
pression in papillary carcinoma
Fig. 2. H&E sections of papillary carcinomas and normal thyroid
tissue in the tissue microarray. (A) Papillary carcinoma showing
papillary structure (×200) and (B) unequivocal nuclear features
(×400). (C) Normal thyroid tissue (×100).
B
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in two cases, for perithyroidal soft tissue was not included
within the specimen. 
Ret protein expression by immunohistochemistry and
clinicopathologic correlation
A total of 72 cases (62.6%) of 115 papillary thyroid carci-
nomas expressed Ret protein. The immunohistochemical
detection of Ret protein was consistently observed in the cyto-
plasm of the tumor cells in more than 30% of the tissue core
for each case. Ret protein expression was absent in the nor-
mal thyroid tissues (Fig. 3). 
The Ret protein expression rate was not different in those
groups with and without regional lymph node metastasis,
perithyroidal extension, and multifocal disease (Table 2). Fur-
thermore, age and sex of the patient group (Table 1), and
the size of the tumor did not influence the expression of Ret
(Table 2). 
CK19 and Ret protein expression
Ninety-three PTCs (80.9%) showed diffuse cytoplasmic
staining of CK19 (Table 3, Fig. 4). As with the Ret protein
Ret
p-value Total
Positive Negative
LN metastasis
Yes 40 (63.5%) 23 (36.5%) 1.00 63 (74.1%)
No 14 (63.6%) 8 (36.4%) 22 (25.9%)
Perithyroidal extension
Yes 52 (61.9%) 32 (38.1%) 1.00 84 (74.3%)
No 18 (62.1%) 11 (37.9%) 29 (25.7%)
Multiplicity
Yes 20 (69.0%) 9 (31.0%) 0.50 29 (25.7%)
No 50 (59.5%) 34 (40.5%) 84 (74.3%)
Size (cm)
Mean 1.7±1.1 2.0±1.1 0.31 1.8±1.1
<1 cm 25 (67.6%) 12 (32.4%) 37 (33.9%)
1-4 cm 40 (58.8%) 28 (41.2%) 68 (62.4%)
>4 cm 3 (75.0%) 1 (25.0%) 4 (3.7%)
Table 2. Clinicopathologic variables and correlation with Ret
protein expression in papillary carcinoma
Fig. 3. (A) Diffuse cytoplasmic staining of the Ret antibody in the tumor tissue (×200). (B) No immunoreactivity in the matched normal
thyroid tissue (×100).
A B
Fig. 4. (A) Diffuse cytoplasmic staining of the tumor cells for CK19 (×200). (B) No immunoreactivity in the matched normal thyroid tissue
(×100).
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expression, CK19 immunoreactivity also had no statistical-
ly significant correlation with the aforementioned clinico-
pathological variables. Of the 115 cases, 7 cases were in lack
of normal thyroid tissue in the specimen and 12 out of the
108 matched normal thyroid tissue showed CK19 immuno-
reactivity in the follicular epithelial cells. 
Of the 115 papillary carcinomas, 62 cases (53.9%) showed
positivity for both CK19 and Ret, and twelve cases (10.4%)
showed negative results for both CK19 and Ret. The percent
agreement of the two antibodies in classic PTC was relative-
ly high, however, it had no statistical significance ( =0.16,
p=0.06) (Table 3). 
DISCUSSION
The RET proto-oncogene has been identified to be respon-
sible for the inherited cancer syndrome MEN 2, and also in-
volved in the molecular pathogenesis of sporadic medullary
thyroid carcinomas, PTCs, and Hirschsprung’s disease (22).
In the pathogenesis of PTC, RET activation has been hypo-
thesized to constitute a specific genetic event and to account
for the characteristic nuclear changes of PTC (23). Sugg et
al. (14). identified RET/PTC rearrangements in the majority
of occult papillary microcarcinomas and lower percentage of
rearrangements in clinically manifest tumors, suggesting a
significant role of RET/PTC rearrangements in the initiation
of PTC. However, the exact role of RET/PTC in the develop-
ment of PTC remains unclear and the prevalence of RET/PTC
rearrangement is ill-defined, varying widely from 2.5-34.5%
among patient series from different geographical regions (9-
12). The existence of geographic variability is shown by com-
parison of the prevalence of RET/PTC activation in differ-
ent studies of sporadic PTCs, all of which have used reverse
transcriptase polymerase chain reaction (24). Santoro et al.
found 11% in the French samples, 33% in the Italian sam-
ples, and 17% in the American samples (6). These discordant
results may be due in part to the different methods and sensi-
tivity of the techniques used, as well as the influence of envi-
ronmental factors such as ionizing radiation exposure. There
have been a few published data in Korea prior to the present
study. Park et al. found no RET/PTC-1, -2, or -3 rearrange-
ment by RT-PCR in 24 cases of PTC in a Korean population
(25), whereas Chung et al. reported a prevalence of 12.9%
in Korean PTCs (26). The latter authors found four out of
thirty-one PTCs to be positive for RET/PTC rearrangement
by RT-PCR, two of which were positive for RET/PTC-2 and
the remaining two were positive for RET/PTC-3, and con-
cluded that the prevalence of RET/PTC rearrangement in a
Korean population is not different from that in other West-
ern countries. Similarly, Chung KW et al. found RET/PTC
rearrangement by RT-PCR in only 2 (9.1%) of the 22 patients
(27). Although the method of detection was different, the
frequency of RET/PTC expression in our study was higher
than that in those prior studies. By immunohistochemistry,
we found 72 cases out of 115 classic PTCs (62.6%) to be posi-
tive for Ret protein expression, which is also in accord with
previous results in Western countries employing immuno-
histochemistry as the method of detection (28).
The immunohistochemical analysis on 3 mm-core tissue
microarray in our study can be reliably used to overcome the
problem of tumor heterogeneity in protein expression through-
out the entire tumor specimen. According to the recently pub-
lished data on validation of tissue microarrays for immuno-
histochemical profiling of cancer specimens by Hoos et al.
(29), the concordance of data between full tissue sections and
tissue microarray was the highest with triplicate 0.6 mm
cores (96-98%) when compared with one and two 0.6 mm
tissue cores. However, even with the one core analysis, the
nonconcordance rate was only 9.4-11.4% (29). When the
larger size of our tissue core and the relatively smaller size of
PTC in general are taken into consideration, the validity of
our immunohistochemical analysis on tissue microarray need
not be in doubt.
Immunohistochemical staining using antibodies against
the Ret tyrosine kinase domain for the detection of RET/PTC
in PTC is based on the assumption that since Ret is not ex-
pressed in thyroid follicular cells lacking RET/PTC activa-
tion, negative Ret-tyrosine kinase immunoreactivity is con-
sistent with lack of RET/PTC rearrangement (30). Further-
more, a good correlation has been shown between immuno-
histochemical reactivity for Ret-tyrosine kinase and RT-PCR
(13, 14). However, the discrepancy in results between groups
employing RT-PCR/in situ hybridization and those using
immunohistochemistry may be explained by the existence
of wild-type RET oncogene. In addition to RET/PTC 1, 2,
and 3 and their variants, it is probable that wild-type RET
oncogene activation plays a role in the development of PTC.
The fact that positive immunoreactivity for RET oncogene
not only detects the product of RET/PTC oncogenes, but also
the products of wild-type RET may account for the high rate
of Ret protein immunoreactivity. 
Many attempts have been made to correlate the presence
of RET/PTC activation with the clinical parameters of human
PTCs. Our results demonstrate that the Ret protein expres-
sion is not influenced by any of the clinicopathologic param-
eters, i.e. age, sex, size of the tumor, multiplicity, lymph node
CK19
Total
Positive Negative
Ret
Positive 62 (53.9%) 10 (8.7%) 72
Negative 31 (27.0%) 12 (10.4%) 43
Total 93 22
=0.16 (15.5%), p=0.06.
Table 3. Percent agreement of Ret and CK19 immunoreactivity
in papillary carcinomaRET/PTC and CK19 Expression in Papillary Thyroid Carcinoma 103
metastasis, and perithyroidal extension. Jhiang et al. proposed
that RET/PTC might be associated with distant metastatic
disease, as 2 of 4 (50%) tumors that had distant metastases
expressed RET/PTC rearrangements compared to 4 of 32
(12%) tumors that did not metastasize (11). Miki et al. found
a higher incidence of RET/PTC expression in cases with extra-
thyroidal invasion than in those without invasion by immuno-
histochemistry (68% vs. 20%, p<0.01), suggesting that RET/
PTC may be related to the local invasion of PTCs (15). How-
ever, other investigators have shown that RET/PTC is more
frequently detected in smaller, slow growing, and less aggres-
sive PTCs, proposing that RET/PTC may serve as a marker
for favorable prognosis (31, 32). It has also been suggested
that RET/PTC positivity correlates with early lymph node
spread but lower metastatic potential (33). This discrepancy
may be explained by the differences in screening methods,
sample preparation, genetic background of patients, and
environmental factors. Thus, it is difficult to compare reports
that have studied different patient populations and used dif-
ferent approaches to detect RET/PTC rearrangements. Also,
it is yet to be determined whether the clinical behavior of
human PTC is affected by differences in RET/PTC expres-
sion levels, and/or the different forms of RET/PTC. It is con-
ceivable that signaling pathways perturbed by RET/PTC
activation in thyroid cells could be overcome by other factors,
if RET/PTC expression occurs at a low level. Larger patient
numbers, longer follow-up times and employment of molec-
ular pathologic methods may provide additional information
in future studies. 
Although we found no prognostic implications of Ret pro-
tein expression in PTCs in a Korean population, consider-
ing its relatively high expression rate detected by immuno-
histochemistry we explored its potential role as an ancillary
tool in the diagnosis of PTC. We analyzed the concordance
rate with CK19, which is reported to be reactive in most
PTCs and used as a useful ancillary diagnostic marker (16,
17, 20). The findings of our study showed 80.9% positivity
to CK19 in the 115 classic PTCs, which are in corrobora-
tion of previous reports that CK19 immunohistochemistry
is a useful ancillary tool for diagnosing PTC (19). Cheung
et al. have reported that CK19 and Ret antibody comprise
an excellent diagnostic panel for PTC along with HBME-1
(28). However, they did not show the percent agreement of
the two antibodies in immunoreactivity. We have found 62
(53.9%) out of 115 PTCs to be positive for both Ret and
CK19, implicating a relatively high percent agreement of
the two antibodies in diagnosing PTC. However, it was sta-
tistically not significant (p=0.06,  =0.16), due in part to
comparatively high percentage of positive immunoreactivi-
ty for CK19. 
Although none of the clinicopathological parameters showed
any correlation with Ret protein expression in our cohort of
115 classic PTCs, RET/PTC oncogene activation is a mark-
er for PTC with potentially useful applications to the diag-
nosis of clinically suspicious thyroid lesions with question-
able cytologic features of PTC as well as to the follow-up of
patients. 
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